Pfizer Inc. (ETR:PFE)
Germany
· Delayed Price · Currency is EUR | Market Cap | 122.07B |
| Revenue (ttm) | 54.48B |
| Net Income (ttm) | 9.18B |
| Shares Out | n/a |
| EPS (ttm) | 1.62 |
| PE Ratio | 13.30 |
| Forward PE | 9.03 |
| Dividend | 1.55 (7.19%) |
| Ex-Dividend Date | Jul 25, 2025 |
| Volume | 28,936 |
| Average Volume | 51,888 |
| Open | 21.56 |
| Previous Close | 21.51 |
| Day's Range | 21.34 - 21.62 |
| 52-Week Range | 18.57 - 27.77 |
| Beta | 0.44 |
| RSI | 54.97 |
| Earnings Date | Aug 5, 2025 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial numbers in USD Financial StatementsNews
Pfizer shares jump over 2% after launch of next-gen 20-valent pneumococcal vaccine in India
Shares of Pfizer Limited rose 2.07% to Rs 5,165.50 on Tuesday, August 12, following the company’s announcement of the launch of its next-generation 20-valent Pneumococcal Polysaccharide Conjugate Vacc...
Pfizer Just Beat Its Earning Estimates. Is This the Beginning of a Turnaround for the Pharmaceutical Stock?
It was a rare breath of fresh air for shareholders.
FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply
View Preview Pfizer Inc.'s (NYSE: PFE) COVID-19 vaccine for children under five may lose U.S. Food and Drug Administration authorization this fall, raising the possibility of supply shortages and pro...
FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply
Pfizer Inc.'s PFE COVID-19 vaccine for children under five may lose U.S. Food and Drug Administration authorization this fall, raising the possibility of supply shortages and prompting Moderna Inc. MR...
Pfizer's Options Frenzy: What You Need to Know
Whales with a lot of money to spend have taken a noticeably bullish stance on Pfizer . Looking at options history for Pfizer (NYSE: PFE) we detected 13 trades. If we consider the specifics of each tr...
Is This Ultra-High Yield Dividend Stock a Steal at a 19% Discount?
A Fallen Giant Pfizer (NYSE:PFE) has been a bitter pill for investors to swallow. Down 19% from its 52-week high of $30.43 per share, PFE stock has plummeted over 50% in the past three years, a stark ...
RFK Jr has slashed vaccine research. You need to know how perilous that is for the world | Devi Sridhar
The avian flu virus is now just one mutation away from easier transmission among humans. Donald Trump’s health chief is a grave risk to world health Prof Devi Sridhar is chair of global public health ...
Pfizer (PFE) Sees Stock Uptick After Q2 Financial Strength
Pfizer (PFE) Sees Stock Uptick After Q2 Financial Strength
Notable healthcare headlines for the week: Pfizer, Eli Lilly, UnitedHealth in focus
Pfizer Covid vaccine for young children may not be renewed by FDA
Email obtained by Guardian says Pfizer was told approval may not be granted, meaning Moderna may have to fill gap Pfizer’s Covid vaccine for young children may not be renewed by the US Food and Drug A...
Pfizer and Arvinas' breast cancer therapy to be reviewed by FDA
GSK, CureVac to receive $740M as COVID vaccine patent dispute with Pfizer, BioNTech settled
GSK to be paid up to £370 million after patent row settles in US
CureVac – a German pharmaceutical company – settled a long-running patent dispute with rival BioNTech and Pfizer in the US on Thursday.
CureVac settles patent dispute litigation with Pfizer and BioNTech
CureVac said on Thursday that the company and GSK have entered an agreement to a resolve patent dispute with Pfizer and BioNTech related to mRNA-based COVID-19 vaccines.
CureVac Resolves Patent Dispute with Pfizer/BioNTech!
CureVac and GSK have settled patent disputes with BioNTech and Pfizer, securing $740 million and future royalties, while paving the way for global mRNA vaccine collaboration. Jetzt den vollständigen A...
EQS-News: CureVac Announces Resolution of Patent Litigation with Pfizer/BioNTech
Issuer: CureVac / Key word(s): Patent CureVac Announces Resolution of Patent Litigation with Pfizer/BioNTech 08.08.2025 / 02:15 CET/CEST The issuer is solely responsible for the content of this announ...
Pfizer's Turnaround Has Truly Started (Earnings Update)
Pfizer Q2: Dividends Speak Louder Than EPS
Trump Tweets Trigger Stock Swings For Tesla, Boeing, Pfizer—And An Insider Trading Inquiry
When President Donald Trump hits "post" on Truth Social , Wall Street braces for impact. What Happened : Various stock prices — Tesla Inc (NASDAQ: TSLA), Boeing Co (NYSE: BA), Pfizer Inc (NYSE: PFE ...
Trump Tweets Trigger Stock Swings For Tesla, Boeing, Pfizer—And An Insider Trading Inquiry
When President Donald Trump hits "post" on Truth Social, Wall Street braces for impact.
Final Trade: PFE, SNV, PLTR & VLO
The final trades of the day with CNBC's Mike Santoli and the “Fast Money” traders.
Final Trade: PFE, SNV, PLTR & VLO
The final trades of the day with CNBCs Mike Santoli and the Fast Money traders.
Pfizer CEO talks lowering drug prices, tariffs, and earnings
Pfizer (PFE) topped second quarter expectations, but looming Trump-era pharmaceutical tariffs remain a concern. Pfizer CEO Albert Bourla joins Market Domination to discuss the company's earnings resul...
Pfizer Inc. (PFE) Q2 2025 Earnings Call Transcript
Why Shares of Pfizer Soared Today
The large pharmaceutical company reported strong second-quarter earnings results.